Catalent Expects to Finish Fiscal 2020 Strong Amid Coronavirus Pandemic
Many businesses have been forced to recalibrate in response to the new uncertainties created by the coronavirus pandemic. That includes drug manufacturing partner Catalent (NYSE: CTLT), although the company has been relatively lucky so far.
A diverse footprint of operating facilities and customer contracts has spared the business from a severe slowdown. In fact, Catalent has reported more of its customers are expecting an increase in demand than a decrease in demand due to circumstances relating to the coronavirus pandemic. Nonetheless, the company was forced to reduce fiscal full-year 2020 net income guidance 4% from previous projections due to the uncertainty of the situation. Here's what investors need to know about the latest operating results.
Image source: Getty Images.
Source Fool.com
